Investing Profile

David Schenkein

VCInvestor
General Partner at GV
gv.com/team/david-schenkein/Boston, Massachusetts
Photo of David Schenkein, General Partner at GV (Google Ventures)
Your Intro Paths to David Schenkein

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Networks David is a member of
Genentech Network
30 CONNECTIONS
GV Network
29 CONNECTIONS

Find David Schenkein on

cb
Current Investing Position
GV (Google Ventures) General Partner
Investment Range
$250K - $50.0M
Sweet Spot
$25.0M
Investments On Record
32
Current Fund Size
$8B

David Schenkein is on these Sector & Stage Rankings

David Schenkein's Investments On Record (18)

CompanyStageDateRound SizeTotal Raised
Mestag Therapeutics
Series UnknownMar 2026$40M
$40M
Co-investors: Issi Rozen (GV (Google Ventures))
EpiBiologics
Series BJan 2026$110M
Series AJul 2023$23M
$200M
Co-investors: Nisa Leung (Qiming Venture Partners), Samuel Bjork (Digitalis Ventures), Laura Brass (MPM BioImpact), Alaa Halawa (Mubadala)
Paradigm
Series BDec 2025$78M
Series AJan 2023$200M
$290M
Co-investors: Niko Bonatsos (General Catalyst), Hemant Taneja (General Catalyst), Bilal Zuberi (Lux Capital), Jared Friedman (Israel Defense Forces), Scott Belsky (A24), Robert Nelsen (ARCH Venture Partners), Alaa Halawa (Mubadala), Balaji Srinivasan, Eoghan McCabe
Pelage Pharmaceuticals
Series BOct 2025$120M
Series AAug 2024$14M
Series AFeb 2024$17M
$150M
Treeline Biosciences
Series ASep 2025$200M
Series AApr 2021$210M
$410M
Prime Medicine
Post Ipo EquityAug 2025$5M
Series BJul 2021$200M
Series AOct 2019$120M
$320M
Co-investors: Robert Nelsen (ARCH Venture Partners)
Rhygaze
Series AJan 2025$86M
$86M
Leyden Labs
Series BJan 2025$70M
Series BJan 2022$140M
Series AMar 2021$47M
$260M
Co-investors: Brook Byers (Kleiner Perkins), Nisa Leung (Qiming Venture Partners)

David Schenkein's Experience

Board Member Regeneron2023 - Present
Board Member Agios Pharmaceuticals2022 - Present
General Partner GV2019 - Present
Board Member Denali Therapeutics2015 - Present
Clinical Professor of Medicine Tufts Medical Center2009 - Present
Chairperson of the Board Agios Pharmaceuticals2019 - 2022
CEO Agios Pharmaceuticals2009 - 2019
Senior Vice President, Clinical Hematology/Oncology Genentech2006 - 2009
Senior Vice President, Clinical Research Millennium Pharmaceuticals2001 - 2006